ClinicalTrials.gg
CompletedNCT01647971Updated Nov 21, 2022

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

A Phase 1/2 interventional study of Ublituximab in Non-Hodgkins Lymphoma, B-cell Lymphoma and Waldenstrom's Macroglobulinemia, sponsored by TG Therapeutics, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-21.

Primary conditionLymphoma, B-CellRegistry: Lymphoma, Non-HodgkinReclassifiedWhy we changed it
Registry
Lymphoma, Non-Hodgkin — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, B-Cell
Why
  1. The study's listed conditions name Lymphoma, B-Cell, a narrower term within Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by TG Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 398 studies in Lymphoma, B-Cell with a site in United States — 91 open to participants now, 157 under way, 12 of them phase 3. Lymphoma, B-Cell · United States.

Enrollment
182nd of 380
39 · median 37
Started
2012
with 8 others
Phase 1/2
75 of 398
20 open now
Registered
96th of 398
by date

Among the 398 studies in Lymphoma, B-Cell with a site in United States, this one is the 182nd largest by enrollment of the 380 interventional ones that give a count, is one of 9 that started in 2012, is one of 75 in phase 1/2, and was the 96th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

91 of the 398 studies in Lymphoma, B-Cell with a site in United States are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 398 studies in Lymphoma, B-Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab.

03

Conditions studied

  • Non-Hodgkins Lymphoma
  • B-cell Lymphoma
  • Waldenstrom's Macroglobulinemia
  • Marginal Zone Lymphoma
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Primary Central Nervous System Lymphoma

Keywords

  • Lymphoma
  • Rituxan
  • Relapsed
  • Refractory
04

In context

Lymphoma, B-Cell Reclassified

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

This study's enrollment of 39 is above the median of 34 across 773 interventional studies indexed under Lymphoma, B-Cell.

Browse Lymphoma, B-Cell studies →

Lead sponsor

TG Therapeutics, Inc. is the lead sponsor of 40 studies on the registry; 9 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.

Compared within Lymphoma, B-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • B-cell Lymphoma
  • Measurable or Evaluable Disease
  • Previously treated with at least one line of rituximab or a rituximab based therapy
  • Patients ineligible for high dose or combination chemotherapy + stem cell transplant
  • (ECOG) Performance Status of 0, 1 or 2
  • No active or chronic infection of or C and no history of based on negative serology

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy, therapy or radiotherapy within 3 weeks of study entry
  • Prior or allogeneic stem cell transplantation within 3 months of study entry
  • History of severe or anaphylaxis to prior rituximab
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, , or psychiatric illness that would limit compliance with study requirements
  • Pregnant women
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    ublituximab

    Phase I: 4 cohorts with IV ublituximab starting with 450 mg followed by 600 mg, 900 mg or 1200 mg in each cohort (3 - 6 patients per cohort). Infusions will be on days 1, 8, 15 and 22 of cycle 1 followed by a planned maintenance with a single infusion monthly starting cycle 3. Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) will have infusions on Days 1, 8 and 15 of cycle 1 \& 2 followed by a planned maintenance with a single infusion monthly starting cycle 3. Expansion of patient enrollment in select cohorts will apply.

    Drug: Ublituximab

Interventions

  • Ublituximab is a novel monoclonal antibody targeting cluster of differentiate 20 (CD20)

07

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    Safety for all study patients will be evaluated by a Data Safety Monitoring Board to determine if feasible to continue with dose escalation

    Time frame: Subjects will be followed for 4 weeks

  2. Maximum Tolerated Dose acceptable for participants

    The Maximum Tolerated Dose will be determined by a Data Safety Monitoring Board

    Time frame: Subjects will be followed for 4 weeks

Secondary outcomes

  1. Efficacy

    Efficacy will include overall response rate, duration of response and progression-free survival

    Time frame: Participants will be evaluated approximately every 8 - 12 weeks

Other outcomes

  1. Pharmacokinetic profile including Peak Plasma Concentration (Cmax)" or "Area Pharmacokinetic profile including Peak Plasma Concentration (Cmax) and Area under the plasma concentration versus time curve (AUC)

    Time frame: Up to 6 months

08

Study locations

8 sites
  • TG Therapeutics Investigational Trial Site
    Huntsville, Alabama 35805, United States
  • TG Therapeutics Investigational Trial Site
    Jonesboro, Arkansas 72401, United States
  • TG Therapeutics Investigational Trial Site
    Athens, Georgia 30607, United States
  • TG Therapeutics Investigational Trial Site
    Macon, Georgia 31201, United States
  • TG Therapeutics Investigational Trial Site
    Bethesda, Maryland 20817, United States
  • TG Therapeutics Investigational Trial Site
    Morristown, New Jersey 07962, United States
  • TG Therapeutics Investigational Trial Site
    New York, New York 10022, United States
  • TG Therapeutics Investigational Trial Site
    Memphis, Tennessee 38120, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2012 to primary completion in May 2015, 34 months.

Of 94 phase 1/2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 96. This study's 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2012
First posted
Jul 24, 2012
StartActual
Jul 19, 2012
Primary completionActual
May 2015
CompletionActual
May 2015
Results delay requested
Oct 21, 2022
Last update
Nov 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01647971
Responsible party
Sponsor
First posted
Jul 24, 2012
Start date
Jul 19, 2012
Primary completion
May 2015
Completion
May 2015
Last update
Nov 21, 2022

Study contacts

TG Therapeutics Clinical Trials
study director · TG Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ublituximab

Start the discussion